Nkarta (NKTX) Other Operating Expenses (2019 - 2020)
Nkarta's quarterly Other Operating Expenses came in at -$37000.0 in Q4 2020, up 98.21% year-on-year from -$18667.2 in Q1 2020, and up 99.91% quarter-over-quarter from -$40.7 million in Q2 2020.
Nkarta has reported Other Operating Expenses for 2 years, with the latest figure at -$37000.0 in Q4 2020.
- For the quarter ending Q4 2020, Other Operating Expenses rose 98.21% year-over-year to -$37000.0; the trailing twelve-month figure through Sep 2021 stood at -$37000.0 (up 99.91% YoY), and the FY2020 full-year result was -$40.2 million, down 3150.08% from the prior year.
- Other Operating Expenses for Q4 2020 stood at -$37000.0, up from -$40.7 million in the prior quarter.
- The five-year high for Other Operating Expenses was $3.4 million in Q3 2019, with the low at -$40.7 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -37,000.00 |
| Jun 30, 2020 | -40.74 Mn |
| Mar 31, 2020 | 578,000.00 |
| Dec 31, 2019 | -2.07 Mn |
| Sep 30, 2019 | 3.38 Mn |